2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 54

Use of Health Plan Data to Assess Feasibility of Large Pragmatic Clinical Trials in Rheumatoid Arthritis
Abstract Number: 64

Use of Moist Snuff and the Risk of Developing Rheumatoid Arthritis; Results From the Swedish Epidemiological Investigation of Rheumatoid Arthritis Study
Abstract Number: 1145

Use of Non-Etanercept Biologics in Children with Juvenile Idiopathic Arthritis: Results From the Biologics for Children with Rheumatic Diseases Study
Abstract Number: 907

Use of Patient Preferences to Inform the Development of Disease Modifying Drugs for Osteoarthritis
Abstract Number: 925

Use of Rheumatology Services for Arthritis: The Role of SES and Geographic Availability of Rheumatologists and Primary Care Physicians
Abstract Number: 1909

Use of Uric Lowering Therapies within a Large Health Care System
Abstract Number: 293

Usefulness of Cardiac Magnetic Resonance in the Assessment of Myocardial Inflammation and Fibrosis in Children Born to Mothers with Anti-SSA/Ro Antibodies: A Prospective Study of 23 Cases and 6 Controls
Abstract Number: 685

Using a Library of Synthetic Autoantigen Mimics to Discover Biomarkers of Systemic Lupus Erythematosus
Abstract Number: 2060

Using the Electronic Medical Record to Increase Rates of Physician Assessment of Lipids in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Quality Improvement Initiative
Abstract Number: 2430

Using the Internet in Help-Seeking As Illness Develops in Early Rheumatoid Arthritis
Abstract Number: 569

Ustekinumab Improves Arthritis-Related and Skin-Related Quality of Life in Patients with Active Psoriatic Arthritis: Patient Reported Outcomes From Randomized and Double Blinded Phase III Psummit I Trial
Abstract Number: 2557

Ustekinumab in Active Psoriatic Arthritis Including Patients Previously Treated with Anti-TNF Agents: Results of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
Abstract Number: 2562

Ustekinumab in Patients with Active Psoriatic Arthritis: Results of the Phase 3, Multicenter, Double-Blind, Placebo-Controlled Psummit I Study
Abstract Number: 559

Utility of Dual-Energy X-Ray absorptiometry Scanning and Risk of Osteoporosis in Ankylosing Spondylitis; A Prospective Study
Abstract Number: 742

Utility of HLA-B5801 Genotyping and Renal Dosing of the Starting Dose of Allopurinol in Preventing Allopurinol Hypersensitivity Syndrome: A Cost-Effectiveness Analysis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].